Japan’s Gunze Expects To Market Artificial Skin In Europe Within Year
This article was originally published in PharmAsia News
Executive Summary
Within the coming year, Japanese firm Gunze expects to begin marketing its Pelnac artificial skin in Europe to treat burns, bedsores and other types of wounds. Pelnac is a collagen sponge that serves as a skin until natural skin grows back into place. Gunze already markets the product in Japan and China through other companies. Pelnac is not yet approved for use in Europe, but the company expects approval during fiscal 2008. (Click here for more - a subscription may be required
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.